Thymalin vs Thymosin Alpha-1
A side-by-side research comparison of Thymalin and Thymosin Alpha-1 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Thymalin | Thymosin Alpha-1 |
|---|---|---|
| Full name | Thymalin (Thymus Extract Peptide) | Thymosin Alpha-1 (Thymalfasin) |
| Category | Immune Support | Immune Support |
| Status | Research compound | Approved internationally (not FDA-approved) |
| Mechanism | Contains bioactive thymic peptides that regulate T-lymphocyte differentiation, restore T-helper/T-suppressor ratios, and enhance phagocyte activity and interferon production. | Activates toll-like receptors (TLR2, TLR9) on dendritic cells, promotes T-cell maturation and differentiation, enhances NK cell cytotoxicity, and modulates cytokine profiles. |
| Molecular weight | ~1000-5000 Da (complex mixture) | 3108.3 Da |
| Half-life | ~4-6 hours | ~2-3 hours |
| Bioavailability | ~80% intramuscular | ~85% subcutaneous |
| Typical dose | 5-10 mg | 1.6-3.2 mg |
| Frequency | Daily for 5-10 days | 2-3x per week |
| Route | Intramuscular injection | Subcutaneous injection |
Thymalin reported benefits
- Immune reconstitution
- T-cell ratio normalization
- Interferon production
- Anti-tumor immunity support
Thymosin Alpha-1 reported benefits
- Enhanced T-cell immunity
- Anti-viral activity
- Dendritic cell activation
- Cancer immunosurveillance
- Vaccine adjuvant effects
Related comparisons
Research and educational reference only. Not medical advice.